1.Clinical Efficacy of Modified Linggui Zhugan Tang in Patients with Obstructive Sleep Apnea-Hypopnea Syndrome of Spleen Deficiency and Dampness Obstruction with Blood Stasis Type and Its Effect on MIF, miR-223, and IL-18
Jun ZHANG ; Mengmei WEI ; Bo LI ; Yi YANG ; Changhui LINGHU ; Mingchang ZHANG ; Zhengxing GE
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(9):171-179
ObjectiveTo investigate the intervention effects of modified Linggui Zhugan Tang (LGZGT) on patients with obstructive sleep apnea-hypopnea syndrome (OSAHS) of the spleen deficiency and dampness obstruction with blood stasis type, reveal its possible mechanisms, and provide a theoretical basis for the clinical treatment of OSAHS with traditional Chinese medicine (TCM). MethodsEighty OSAHS patients with spleen deficiency and dampness obstruction with blood stasis were randomly assigned to a control group and an observation group (1∶1) using a random number table, with 40 patients in each group. The control group received standard basic treatment combined with oral Doxofylline tablets, while the observation group received standard basic treatment combined with modified LGZGT. Serum levels of macrophage migration inhibitory factor (MIF), microRNA-223 (miR-223), and interleukin-18 (IL-18) were measured by enzyme-linked immunosorbent assay (ELISA), and the mRNA expression levels of MIF, miR-223, and IL-18 were measured by real-time quantitative polymerase chain reaction (Real-time PCR). After two months of treatment, the total clinical efficacy, apnea-hypopnea index (AHI), lowest nocturnal oxygen saturation (LSpO2), body mass index (BMI), TCM syndrome scores, and expression levels of MIF, miR-223, and IL-18 before and after treatment were compared between the two groups. Correlations between MIF, miR-223, IL-18 and AHI and LSpO2 were also analyzed. ResultsCompared with the control group, the observation group showed a significantly higher total clinical effective rate (P<0.01, Z=-3.49). Within the control group, no significant changes were observed in AHI, LSpO2, BMI, TCM syndrome scores, or MIF, miR-223, IL-18 levels and their mRNAs after treatment. In the observation group, AHI, BMI, TCM syndrome scores, and MIF and IL-18 levels and their mRNAs decreased significantly, while LSpO2 increased significantly (P<0.01). After treatment, compared with the control group, the observation group exhibited significantly lower AHI, BMI, TCM syndrome scores, and MIF and IL-18 levels and their mRNAs, and significantly higher LSpO2 (P<0.01). Correlation analysis showed that MIF and IL-18 were positively correlated with AHI (P<0.01) and negatively correlated with LSpO2 (P<0.01), whereas miR-223 was negatively correlated with AHI (P<0.01) and positively correlated with LSpO2 (P<0.01). ConclusionModified LGZGT may improve OSAHS of the spleen deficiency and dampness obstruction with blood stasis type by reducing airway inflammatory factors, alleviating airway inflammation, relieving airway edema and stenosis, and improving airway obstruction.
2.Optimizing oral antithrombotic therapy in patients post percutaneous coronary intervention
Chinese Journal of Interventional Cardiology 2025;33(11):601-613
Oral anti-thrombotic medication management is crucial for patients post percutaneous coronary intervention(PCI).Identifying the optimal balance between ischemic and hemorrhagic risks has consistently been a highly concerning and urgent issue for clinicians.Given individual variations in risk and drug responses,guideline-recommended strategies may not suit all patients.Recent studies have explored tailored anti-thrombotic strategies for diverse groups,providing evidence for guideline revisions and offering multiple clinical treatment options.However,patient assessment,adjustment timing,and strategy formulation lack standardization and flexibility,necessitating professional consensus.This consensus statement,carefully crafted to meet clinical needs,emphasizes dynamic assessment and holistic management,prioritizing individual differences and patient adherence.It aims to offer practical,optimized anti-thrombotic regimens to improve patients' long-term outcomes.
3.Quality control report of Heart Valve Center in 2024
Da-xin ZHOU ; Yong-jian WU ; Jian-an WANG ; Jun-bo GE
Chinese Journal of Interventional Cardiology 2025;33(11):614-619
With the aging of the population,the disease burden of heart valve disease in China has significantly increased.In recent years,the interventional treatment for heart valve disease has flourished,among which transcatheter aortic valve replacement(TAVR)has become the first-line treatment for elderly patients with aortic valve stenosis.China started relatively late in the field of interventional treatment for heart valve disease.The construction of heart valve centers helps to standardize the diagnosis and interventional treatment of heart valve disease in China and improve the management of prognosis for patients.Up to December 2024,a total of 453 centers have participated in the construction of heart valve centers,including 100 construction centers and 40 certification centers.The National Transcatheter Valve Therapeutics Registry(NTCVR)database has reported a total of 28 594 cases,with approximately 50%of Chinese TAVR cases recorded in NTCVR database.The construction of the heart valve centers has shown initial results,significantly optimizing the process of diagnosis and treatment of heart valve disease and improving the prognosis.At present,there are still many shortcomings in the construction of heart valve centers.For example,the follow-up rate of patients after discharge is low,and long-term management after discharge needs to be further improved.There is still a gap in some indicators between construction centers and certification centers,and the promotion of high-quality management of interventional treatment of heart valve disease in China is still a long way to go.
4.Quality control report on the Panvascular Disease Management Center database(2024)
Chinese Journal of Interventional Cardiology 2025;33(7):368-375
To improve the diagnosis,treatment,and management of panvascular diseases,under the guidance of the National Clinical Research Center for Interventional Medicine,the Panvascular Medicine Expert Committee established a standardized registry database for panvascular diseases and encouraged all Panvascular Disease Management Centers(PVMCs)to submit case data.By the end of 2024,a total of 143 640 case records had been submitted by PVMCs.This report systematically evaluates the data quality of the database.The results show that the overall average completeness rate of mandatory fields was 79.23%.Among the patients,56.13%were male,with an average age of 60.71 years.The major cardiovascular risk factors included hypertension(36.96%),dyslipidemia(28.86%),diabetes(17.67%)and smoking(17.40%).Regarding medication use,statins had the highest utilization rate(95.86%).When analyzed by drug category-antiplatelet,anticoagulant,glucose-lowering,and antihypertensive medications-aspirin(85.71%),rivaroxaban(72.91%),sodium-glucose co-transporter 2 inhibitors(45.58%),and beta-blockers(50.01%)were the most frequently used in their respective groups.In the atherosclerotic cardiovascular disease(ASCVD)risk assessment,the proportions of high-risk,very high-risk,and extremely high-risk patients were 11.98%,14.57%,and 10.45%,respectively.At the 12-month follow-up after registration,the average total cholesterol level showed a significant decrease[(3.51±0.88)mmol/L vs.(4.82±1.21)mmol/L],while the average systolic blood pressure exhibited an increasing trend[(140.7±24.2)mmHg vs.(135.2±17.12)mmHg].As the first standardized,cross-disciplinary,multi-center collaborative database in China,it integrates multidimensional data,including risk factors,vascular lesion characteristics,and disease diagnosis and treatment measures.It covers the full spectrum of patients,from early high-risk populations to advanced ASCVD cases,with an emphasis on collecting imaging and biomarker data and tracking long-term clinical outcomes.We believe this database will provide high-quality data for precise risk stratification,optimized treatment,and real-world research in panvascular diseases.Through continuous upgrades of the information system and improvements in the quality control framework,the accuracy,completeness,and usability of the database have been further enhanced,contributing to the achievement of the"Healthy China"initiative's goal of reducing cardiovascular events.
5.Allicin alleviates senna-induced diarrhea in mice through modulation of inflammation and oxidative stress
Qing ZHOU ; Jia-min WU ; Mo GUO ; Yao-yu ZHAO ; Lei HUANG ; Fei GE ; Pang-bo YANG ; Yuan-yuan QIN ; Yu WANG ; Jun GUO ; Shan GAO
Chinese Pharmacological Bulletin 2025;41(10):1906-1914
Aim To study the therapeutic effect of al-licin on senna-induced diarrhea in mice and to explore the underlying mechanism.Methods Forty-eight C57BL/6J mice were randomly divided into six groups:control,model,loperamide positive control group(2 mg·kg-1),allicin low-dose group(6 mg·kg-1),allicin medium-dose group(12 mg·kg-1)and allicin high-dose group(18 mg·kg-1).Except for the con-trol group,the diarrhea model was induced in the other groups by intragastric administration of senna leaf ex-tract.After drug administration,several diarrhea indi-ces were measured:the rate of loose stools,diarrhea index,accumulated frequency of loose stools at differ-ent time points within 5 hours,and small intestine pro-pelling rate.Serum levels of TNF-α and IL-6 were de-tected by ELISA.Serum NO content was determined u-sing the Griess method.The activities of SOD and CAT,as well as MDA content in the ileum and colon,were measured.The pathological changes and the ex-pression of mRNA related to intestinal barrier proteins in the ileum and colon were evaluated using HE stai-ning and RT-qPCR.Results Allicin improved diar-rhea symptoms in mice induced by senna leaf.It re-duced the rate of loose stools,diarrhea index,cumula-tive number of loose stools in five hours,and the intes-tinal propulsion rate.Allicin also protected the intesti-nal mucosa,decreased serum TNF-α and IL-6 levels,and lowered MDA content in the intestines.It in-creased serum NO levels and enhanced SOD and CAT activities in the intestines.Additionally,allicin upreg-ulated the mRNA expression of AQP1,AQP4,and ZO-1 in intestinal tissues.Conclusions Allicin has a significant therapeutic effect on senna-induced diarrhea in mice.The underlying molecular mechanisms may involve anti-inflammatory and antioxidant effects,in-creased NO content,and upregulation of mRNA ex-pression of aquaporins and tight-junction proteins.
6.Sperm tRNA-derived fragments expression is potentially linked to abstinence-related improvement of sperm quality.
Xi-Ren JI ; Rui-Jun WANG ; Zeng-Hui HUANG ; Hui-Lan WU ; Xiu-Hai HUANG ; Hao BO ; Ge LIN ; Wen-Bing ZHU ; Chuan HUANG
Asian Journal of Andrology 2025;27(5):638-645
Recent studies have shown that shorter periods of ejaculatory abstinence may enhance certain sperm parameters, but the molecular mechanisms underlying these improvements are still unclear. This study explored whether reduced abstinence periods could improve semen quality, particularly for use in assisted reproductive technologies (ART). We analyzed semen samples from men with normal sperm counts ( n = 101) and those with low sperm motility or concentration ( n = 53) after 3-7 days of abstinence and then after 1-3 h of abstinence, obtained from the Reproductive & Genetic Hospital of CITIC-Xiangya (Changsha, China). Physiological and biochemical sperm parameters were evaluated, and the dynamics of transfer RNA (tRNA)-derived fragments (tRFs) were analyzed using deep RNA sequencing in five consecutive samples from men with normal sperm counts. Our results revealed significant improvement in sperm motility and a decrease in the DNA fragmentation index after the 1- to 3-h abstinence period. Additionally, we identified 245 differentially expressed tRFs, and the mitogen-activated protein kinase (MAPK) signaling pathway was the most enriched. Further investigations showed significant changes in tRF-Lys-TTT and its target gene mitogen-activated protein kinase kinase 2 ( MAP2K2 ), which indicates a role of tRFs in improving sperm function. These findings provide new insights into how shorter abstinence periods influence sperm quality and suggest that tRFs may serve as biomarkers for male fertility. This research highlights the potential for optimizing ART protocols and improving reproductive outcomes through molecular approaches that target sperm function.
Male
;
Humans
;
Spermatozoa/metabolism*
;
RNA, Transfer/genetics*
;
Sperm Motility/genetics*
;
Adult
;
Semen Analysis
;
Sexual Abstinence/physiology*
;
Sperm Count
;
DNA Fragmentation
7.Quality control report on the Panvascular Disease Management Center database(2024)
Chinese Journal of Interventional Cardiology 2025;33(7):368-375
To improve the diagnosis,treatment,and management of panvascular diseases,under the guidance of the National Clinical Research Center for Interventional Medicine,the Panvascular Medicine Expert Committee established a standardized registry database for panvascular diseases and encouraged all Panvascular Disease Management Centers(PVMCs)to submit case data.By the end of 2024,a total of 143 640 case records had been submitted by PVMCs.This report systematically evaluates the data quality of the database.The results show that the overall average completeness rate of mandatory fields was 79.23%.Among the patients,56.13%were male,with an average age of 60.71 years.The major cardiovascular risk factors included hypertension(36.96%),dyslipidemia(28.86%),diabetes(17.67%)and smoking(17.40%).Regarding medication use,statins had the highest utilization rate(95.86%).When analyzed by drug category-antiplatelet,anticoagulant,glucose-lowering,and antihypertensive medications-aspirin(85.71%),rivaroxaban(72.91%),sodium-glucose co-transporter 2 inhibitors(45.58%),and beta-blockers(50.01%)were the most frequently used in their respective groups.In the atherosclerotic cardiovascular disease(ASCVD)risk assessment,the proportions of high-risk,very high-risk,and extremely high-risk patients were 11.98%,14.57%,and 10.45%,respectively.At the 12-month follow-up after registration,the average total cholesterol level showed a significant decrease[(3.51±0.88)mmol/L vs.(4.82±1.21)mmol/L],while the average systolic blood pressure exhibited an increasing trend[(140.7±24.2)mmHg vs.(135.2±17.12)mmHg].As the first standardized,cross-disciplinary,multi-center collaborative database in China,it integrates multidimensional data,including risk factors,vascular lesion characteristics,and disease diagnosis and treatment measures.It covers the full spectrum of patients,from early high-risk populations to advanced ASCVD cases,with an emphasis on collecting imaging and biomarker data and tracking long-term clinical outcomes.We believe this database will provide high-quality data for precise risk stratification,optimized treatment,and real-world research in panvascular diseases.Through continuous upgrades of the information system and improvements in the quality control framework,the accuracy,completeness,and usability of the database have been further enhanced,contributing to the achievement of the"Healthy China"initiative's goal of reducing cardiovascular events.
8.Expert consensus on clinical pathway of percutaneous renal denervation therapy for hypertension in China(2025)
China Heart HOUSE ; Yu-jie ZHOU ; Ning-ling SUN ; Wei-min WANG ; Jun-bo GE
Chinese Journal of Interventional Cardiology 2025;33(9):481-490
Percutaneous renal denervation(RDN)is a minimally invasive interventional treatment for hypertension that has been used in clinics at home and abroad,primarily for patients with resistant hypertension or who cannot tolerate antihypertensive drugs.Current clinical studies have confirmed the safety and efficacy of this technique.As RDN is still in its promotional and popularization stage,the expert group has written this clinical pathway to promote the orderly implementation of this technology,standardize the operating process,and standardize diagnostic and therapeutic behaviors.The pathway describes the clinical assessment of patients in detail(including indications,contraindications,and the patient screening process),the standardized operating process for RDN(including perioperative medication,anaesthesia,ablation,and management of complications),and the postoperative follow-up plan(including follow-up content,methods,and timing).It is hoped that this will serve as a reference for physicians involved in RDN clinical work,standardize diagnostic and therapeutic behaviors,and promote the standardized,precise,and sustainable development of the RDN discipline.
9.Optimizing oral antithrombotic therapy in patients post percutaneous coronary intervention
Chinese Journal of Interventional Cardiology 2025;33(11):601-613
Oral anti-thrombotic medication management is crucial for patients post percutaneous coronary intervention(PCI).Identifying the optimal balance between ischemic and hemorrhagic risks has consistently been a highly concerning and urgent issue for clinicians.Given individual variations in risk and drug responses,guideline-recommended strategies may not suit all patients.Recent studies have explored tailored anti-thrombotic strategies for diverse groups,providing evidence for guideline revisions and offering multiple clinical treatment options.However,patient assessment,adjustment timing,and strategy formulation lack standardization and flexibility,necessitating professional consensus.This consensus statement,carefully crafted to meet clinical needs,emphasizes dynamic assessment and holistic management,prioritizing individual differences and patient adherence.It aims to offer practical,optimized anti-thrombotic regimens to improve patients' long-term outcomes.
10.Quality control report of Heart Valve Center in 2024
Da-xin ZHOU ; Yong-jian WU ; Jian-an WANG ; Jun-bo GE
Chinese Journal of Interventional Cardiology 2025;33(11):614-619
With the aging of the population,the disease burden of heart valve disease in China has significantly increased.In recent years,the interventional treatment for heart valve disease has flourished,among which transcatheter aortic valve replacement(TAVR)has become the first-line treatment for elderly patients with aortic valve stenosis.China started relatively late in the field of interventional treatment for heart valve disease.The construction of heart valve centers helps to standardize the diagnosis and interventional treatment of heart valve disease in China and improve the management of prognosis for patients.Up to December 2024,a total of 453 centers have participated in the construction of heart valve centers,including 100 construction centers and 40 certification centers.The National Transcatheter Valve Therapeutics Registry(NTCVR)database has reported a total of 28 594 cases,with approximately 50%of Chinese TAVR cases recorded in NTCVR database.The construction of the heart valve centers has shown initial results,significantly optimizing the process of diagnosis and treatment of heart valve disease and improving the prognosis.At present,there are still many shortcomings in the construction of heart valve centers.For example,the follow-up rate of patients after discharge is low,and long-term management after discharge needs to be further improved.There is still a gap in some indicators between construction centers and certification centers,and the promotion of high-quality management of interventional treatment of heart valve disease in China is still a long way to go.

Result Analysis
Print
Save
E-mail